Cargando…

AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery

BACKGROUND: Recent DNA/RNA sequencing and other multi-omics technologies have advanced the understanding of the biology and pathophysiology of AD, yet there is still a lack of disease-modifying treatments for AD. A new approach to integration of the genome, transcriptome, proteome, and human interac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yadi, Fang, Jiansong, Bekris, Lynn M., Kim, Young Heon, Pieper, Andrew A., Leverenz, James B., Cummings, Jeffrey, Cheng, Feixiong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804907/ https://www.ncbi.nlm.nih.gov/pubmed/33441136 http://dx.doi.org/10.1186/s13195-020-00760-w

Ejemplares similares

The Alzheimer's Cell Atlas (TACA): A single‐cell molecular map for translational therapeutics accelerator in Alzheimer's disease
por: Zhou, Yadi, et al.
Publicado: (2022)

Interpretable deep learning translation of GWAS and multi-omics findings to identify pathobiology and drug repurposing in Alzheimer’s disease
por: Xu, Jielin, et al.
Publicado: (2022)

Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease
por: Xu, Jielin, et al.
Publicado: (2021)

AlzPlatform: An Alzheimer’s Disease Domain-Specific Chemogenomics Knowledgebase for Polypharmacology and Target Identification Research
por: Liu, Haibin, et al.
Publicado: (2014)

AlzPathway: a comprehensive map of signaling pathways of Alzheimer’s disease
por: Mizuno, Satoshi, et al.
Publicado: (2012)

Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease
por: Fang, Jiansong, et al.
Publicado: (2022)

Signature of Alzheimer’s Disease in Intestinal Microbiome: Results From the AlzBiom Study
por: Laske, Christoph, et al.
Publicado: (2022)

AlzPharm: integration of neurodegeneration data using RDF
por: Lam, Hugo YK, et al.
Publicado: (2007)

Temporal Ordering of Inflammatory Analytes sTNFR2 and sTREM2 in Relation to Alzheimer's Disease Biomarkers and Clinical Outcomes
por: Pillai, Jagan A., et al.
Publicado: (2021)

Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease
por: Hey, John A., et al.
Publicado: (2017)

Alzheimer's disease drug development pipeline: 2023
por: Cummings, Jeffrey, et al.
Publicado: (2023)

Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease: The AMARANTH and DAYBREAK-ALZ Randomized Clinical Trials
por: Wessels, Alette M., et al.
Publicado: (2020)

Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer’s disease brain extracts
por: Sandberg, Anders, et al.
Publicado: (2022)

Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer’s disease
por: Pillai, Jagan A., et al.
Publicado: (2023)

Key inflammatory pathway activations in the MCI stage of Alzheimer’s disease
por: Pillai, Jagan A., et al.
Publicado: (2019)

Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings
por: Wessels, Alette M., et al.
Publicado: (2023)

Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain
por: Hey, John A., et al.
Publicado: (2018)

An omics perspective on drug target discovery platforms
por: Paananen, Jussi, et al.
Publicado: (2019)

CAD-ALZ: A Blockwise Fine-Tuning Strategy on Convolutional Model and Random Forest Classifier for Recognition of Multistage Alzheimer’s Disease
por: Abbas, Qaisar, et al.
Publicado: (2023)

TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease
por: Salloway, Stephen, et al.
Publicado: (2023)

TNFRSF1B Gene Variants and Related Soluble TNFR2 Levels Impact Resilience in Alzheimer's Disease
por: Pillai, Jagan A., et al.
Publicado: (2021)

My personal mutanome: a computational genomic medicine platform for searching network perturbing alleles linking genotype to phenotype
por: Zhou, Yadi, et al.
Publicado: (2021)

Potential role of miRNA-140 in Alzheimer’s disease
por: Akhter, Rumana, et al.
Publicado: (2019)

Meta Analysis of Human AlzGene Database: Benefits and Limitations of Using C. elegans for the Study of Alzheimer's Disease and Co-morbid Conditions
por: Vahdati Nia, Behrad, et al.
Publicado: (2017)

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
por: Tolar, Martin, et al.
Publicado: (2020)

Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment
por: Zhou, Yadi, et al.
Publicado: (2021)

Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment
por: Zhou, Yadi, et al.
Publicado: (2021)

The clinical use of blood-test factors for Alzheimer’s disease: improving the prediction of cerebral amyloid deposition by the QPLEX(TM)Alz plus assay kit
por: Kim, Haeng Jun, et al.
Publicado: (2021)

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial
por: Pontecorvo, Michael J., et al.
Publicado: (2022)

Application of combined omics platforms to accelerate biomedical discovery in diabesity
por: Kurland, Irwin J, et al.
Publicado: (2013)

Performance of the QPLEX™ Alz plus assay, a novel multiplex kit for screening cerebral amyloid deposition
por: Park, Jong-Chan, et al.
Publicado: (2021)

A Feasibility Study of AlzLife 40 Hz Sensory Therapy in Patients with MCI and Early AD
por: McNett, Sienna D., et al.
Publicado: (2023)

Inflammatory pathway analytes predicting rapid cognitive decline in MCI stage of Alzheimer’s disease
por: Pillai, Jagan A., et al.
Publicado: (2020)

AlzEye: longitudinal record-level linkage of ophthalmic imaging and hospital admissions of 353 157 patients in London, UK
por: Wagner, Siegfried Karl, et al.
Publicado: (2022)

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial
por: Shcherbinin, Sergey, et al.
Publicado: (2022)

Longitudinal change in regional brain volumes with exposure to repetitive head impacts
por: Bernick, Charles, et al.
Publicado: (2020)

eGPS 1.0: comprehensive software for multi-omic and evolutionary analyses
por: Yu, Dalang, et al.
Publicado: (2019)

H-InvDB in 2013: an omics study platform for human functional gene and transcript discovery
por: Takeda, Jun-ichi, et al.
Publicado: (2013)

MONET: Multi-omic module discovery by omic selection
por: Rappoport, Nimrod, et al.
Publicado: (2020)

The omics discovery REST interface
por: Dass, Gaurhari, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sf942djvjgsjdtfh8860glnsmq